Imaging in Breast Cancer: Single-photon Computed Tomography and Positron-emission Tomography

Overview

Journal Breast Cancer Res

Specialty Oncology

Date 2005 Jul 1

PMID 15987467

Citations 31

Authors

Francois Benard

Eric Turcotte

Affiliations

Soon will be listed here.

Abstract

Although mammography remains a key imaging method for the early detection and screening of breast cancer, the overall accuracy of this test remains low. Several radiopharmaceuticals have been proposed as adjunct imaging methods to characterize breast masses by single-photon-emission computed tomography (SPECT) and positron-emission tomography (PET). Useful in characterizing indeterminate palpable masses and in the detection of axillary metastases, these techniques are insufficiently sensitive to detect subcentimetric tumor deposits. Their role in staging nodal involvement of the axillary areas therefore currently remains limited. Several enzymes and receptors have been targeted for imaging breast cancers with PET. [18F]fluorodeoxyglucose is particularly useful in the detection and staging of recurrent breast cancer and in assessing the response to chemotherapy. Several other ligands targeting proliferative activity, protein synthesis, and hormone and cell-membrane receptors may complement this approach by providing unique information about biological characteristics of breast cancer across primary and metastatic tumor sites.

Citing Articles

Targeting the Oxytocin Receptor for Breast Cancer Management: A Niche for Peptide Tracers.

Kalaba P, Sanchez de la Rosa C, Moller A, Alewood P, Muttenthaler M J Med Chem. 2024; 67(3):1625-1640.

PMID: 38235665 PMC: 10859963. DOI: 10.1021/acs.jmedchem.3c01089.

Concanavalin A-conjugated gold nanoparticle/silica quantum dot (AuNPs/SiQDs-Con A)-based platform as a fluorescent nanoprobe for the bioimaging of glycan-positive cancer cells.

Jafarzadeh S, Bargahi N, Shamloo H, Soleymani J RSC Adv. 2022; 12(14):8492-8501.

PMID: 35424830 PMC: 8984933. DOI: 10.1039/d2ra00035k.

Diabetes, Obesity, and Inflammation: Impact on Clinical and Radiographic Features of Breast Cancer.

Miller B, Chalfant H, Thomas A, Wellberg E, Henson C, McNally M Int J Mol Sci. 2021; 22(5).

PMID: 33803201 PMC: 7963150. DOI: 10.3390/ijms22052757.

Positron Emission Mammography (PEM) in the diagnosis of breast cancer: A systematic review and economic evaluation.

Keshavarz K, Jafari M, Lotfi F, Bastani P, Salesi M, Gheisari F Med J Islam Repub Iran. 2020; 34:100.

PMID: 33315994 PMC: 7722955. DOI: 10.34171/mjiri.34.100.

PET Imaging Agents (FES, FFNP, and FDHT) for Estrogen, Androgen, and Progesterone Receptors to Improve Management of Breast and Prostate Cancers by Functional Imaging.

Katzenellenbogen J Cancers (Basel). 2020; 12(8).

PMID: 32718075 PMC: 7465097. DOI: 10.3390/cancers12082020.

References

Avril N, Menzel M, Dose J, Schelling M, Weber W, Janicke F . Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med. 2001; 42(1):9-16. View

Shiue C, Shiue G, Benard F, Visonneau S, Santoli D, Alavi A . N-(n-Benzylpiperidin-4-yl)-2-[18F]fluorobenzamide: a potential ligand for PET imaging of breast cancer. Nucl Med Biol. 2001; 27(8):763-7. DOI: 10.1016/s0969-8051(00)00161-x. View

Kao C, Tsai S, Liu T, Ho Y, Wang J, Ho S . P-Glycoprotein and multidrug resistance-related protein expressions in relation to technetium-99m methoxyisobutylisonitrile scintimammography findings. Cancer Res. 2001; 61(4):1412-4. View

Greco M, Crippa F, Agresti R, Seregni E, Gerali A, Giovanazzi R . Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management. J Natl Cancer Inst. 2001; 93(8):630-5. DOI: 10.1093/jnci/93.8.630. View

Schirrmeister H, Kuhn T, Guhlmann A, Santjohanser C, Horster T, Nussle K . Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med. 2001; 28(3):351-8. DOI: 10.1007/s002590000448. View

Mortimer J, Dehdashti F, Siegel B, Trinkaus K, Katzenellenbogen J, Welch M . Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol. 2001; 19(11):2797-803. DOI: 10.1200/JCO.2001.19.11.2797. View

Eubank W, Mankoff D, Takasugi J, Vesselle H, Eary J, Shanley T . 18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol. 2001; 19(15):3516-23. DOI: 10.1200/JCO.2001.19.15.3516. View

Kim T, Moon W, Lee D, Chung J, Lee M, Youn Y . Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer. World J Surg. 2001; 25(7):829-34. DOI: 10.1007/s002680020095. View

Brix G, Henze M, Knopp M, Lucht R, Doll J, Junkermann H . Comparison of pharmacokinetic MRI and [18F] fluorodeoxyglucose PET in the diagnosis of breast cancer: initial experience. Eur Radiol. 2001; 11(10):2058-70. DOI: 10.1007/s003300100944. View

10.

Hustinx R, Benard F, Alavi A . Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med. 2002; 32(1):35-46. DOI: 10.1053/snuc.2002.29272. View

11.

Mankoff D, Dunnwald L, Gralow J, Ellis G, Charlop A, Lawton T . Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med. 2002; 43(4):500-9. View

12.

Yang S, Liang J, Lin F, Kao C, Lin C, Lee C . Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol. 2002; 128(6):325-8. DOI: 10.1007/s00432-002-0342-5. View

13.

Tiling R, Linke R, Kessler M, Untch M, Sommer H, Brinkbaumer K . [Breast scintigraphy using 99mTc-sestamibi--use and limitations]. Nuklearmedizin. 2002; 41(3):148-56. View

14.

Suarez M, Perez-Castejon M, Jimenez A, Domper M, Ruiz G, Montz R . Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med. 2002; 46(2):113-21. View

15.

Seimbille Y, Rousseau J, Benard F, Morin C, Ali H, Avvakumov G . 18F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals. Steroids. 2002; 67(9):765-75. DOI: 10.1016/s0039-128x(02)00025-9. View

16.

Stafford S, Gralow J, Schubert E, Rinn K, Dunnwald L, Livingston R . Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol. 2002; 9(8):913-21. DOI: 10.1016/s1076-6332(03)80461-0. View

17.

Jansson T, Westlin J, Ahlstrom H, Lilja A, Langstrom B, Bergh J . Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation?. J Clin Oncol. 1995; 13(6):1470-7. DOI: 10.1200/JCO.1995.13.6.1470. View

18.

John C, Vilner B, Gulden M, Efange S, Langason R, Moody T . Synthesis and pharmacological characterization of 4-[125I]-N-(N-benzylpiperidin-4-yl)-4-iodobenzamide: a high affinity sigma receptor ligand for potential imaging of breast cancer. Cancer Res. 1995; 55(14):3022-7. View

19.

Clavo A, Brown R, Wahl R . Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med. 1995; 36(9):1625-32. View

20.

Dehdashti F, Mortimer J, Siegel B, Griffeth L, Bonasera T, Fusselman M . Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med. 1995; 36(10):1766-74. View